Business Context and Reporting Period
This Form 8-K Current Report was filed by ReShape Lifesciences Inc. (trading symbol: RSLS) on July 27, 2022. The filing discloses significant changes in executive leadership and board composition effective August 15, 2022. The company is incorporated in Delaware and lists its common stock on The Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive appointments, departures, and associated compensation arrangements.
Material Changes
- Executive Departure: Bart Bandy has separated from the Company as President and Chief Executive Officer and resigned from the Board of Directors to pursue other opportunities.
- Executive Appointment: Paul F. Hickey was appointed President, Chief Executive Officer, and a member of the Board of Directors, effective August 15, 2022.
- Interim Leadership: Thomas Stankovich, Chief Financial Officer, will serve as Interim President and Chief Executive Officer until Mr. Hickey's start date.
- Board Role Change: Dan W. Gladney, current Chair of the Board, will assume a more active role as Executive Chair.
Compensation, Outlook, and Risks
New CEO Compensation (Paul F. Hickey)
- Base Salary: $400,000 annually.
- Bonus: Potential annual bonus of up to 50% of base salary (prorated for 2022).
- Equity Grant: Stock option to purchase shares equal to 4% of outstanding common stock on a fully-diluted basis. Options vest 25% after one year and monthly thereafter for 36 months.
- Future Equity: An additional award will be granted following the first financing offering post-start date to maintain the 4% fully diluted ownership percentage.
- Severance: 12 months of base salary payable as salary continuation if terminated without cause or resigns for good reason, subject to a release of claims.
Interim CEO Retention (Thomas Stankovich)
- Retention Bonus: 100% of target 2022 cash bonus, regardless of actual performance, if employed until December 31, 2022, or if terminated without cause/resigns for good reason before that date.
Departure Benefits (Bart Bandy)
- Severance benefits provided pursuant to his employment agreement dated August 26, 2019, under a separation agreement and general release.
Outlook and Risks: The filing does not contain specific financial guidance or market outlook. The primary risk disclosed relates to the transition of leadership and the associated compensation costs.
Investor Verification Checklist
- Verify the exact number of shares underlying Mr. Hickey's 4% stock option grant based on the fully-diluted share count as of the grant date.
- Review the full text of the Offer Letter (Exhibit 10.1) and Retention Agreement (Exhibit 10.2) for specific conditions and clawback provisions.
- Confirm the specific severance amount payable to Mr. Bandy under his 2019 employment agreement.
- Monitor the company's capital raising activities to determine the timing and size of Mr. Hickey's additional equity award.